Oxurion Overview

  • Year Founded
  • 1991

Year Founded

  • Status
  • Public

  • Employees
  • 26

Employees

  • Stock Symbol
  • OXUR

Stock Symbol

  • Investments
  • 4

Oxurion General Information

Description

Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) covering the full clinical research value chain across Europe.

Contact Information

Website
www.oxurion.com
Formerly Known As
ThromboGenics
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Gaston Geenslaan 1
  • 3001 Leuven
  • Belgium
+32 016
Primary Industry
Other Pharmaceuticals and Biotechnology
Stock Exchange
BRU
Vertical(s)
Corporate Office
  • Gaston Geenslaan 1
  • 3001 Leuven
  • Belgium
+32 016

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oxurion Stock Performance

As of 19-Nov-2026, Oxurion’s current market cap is $255K with 232M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$255K 232M 2.79M $0.12

Oxurion Financials Summary

As of 30-Jun-2026, Oxurion has a trailing 12-month revenue of $1.34M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 13,159 13,243 12,916 13,123
Revenue 1,337 626 3 285
EBITDA (2,984) (4,085) 300 (20,215)
Net Income (4,035) (4,205) 129 (20,526)
Total Assets 3,922 4,493 5,926 7,240
Total Debt 13,143 13,440 11,787 13,634
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oxurion Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oxurion‘s full profile, request access.

Request a free trial

Oxurion Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) co
Other Pharmaceuticals and Biotechnology
Leuven, Belgium
26 As of 2025

Andover, MA
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oxurion Competitors (2)

One of Oxurion’s 2 competitors is Ora (Massachusetts), a Private Equity-Backed company based in Andover, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ora (Massachusetts) Private Equity-Backed Andover, MA
Novartis Corporation Basel, Switzerland
You’re viewing 2 of 2 competitors. Get the full list »

Oxurion Patents

Oxurion Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023148016-A1 Biomarker for plasma kallikrein inhibitor therapy response Inactive 04-Feb-2022
WO-2023144030-A1 Plasma kallikrein inhibitor therapy for anti-vegf sensitization Inactive 31-Jan-2022
WO-2021198534-A1 Plasma kallikrein inhibitors for use in the treatment of coronaviral disease Inactive 04-Apr-2020
WO-2021165206-A1 Treatment of dry amd with integrin antagonists Inactive 19-Feb-2020
AU-2019326932-A1 Integrin antagonists Inactive 17-Aug-2018 C07D471/04
To view Oxurion’s complete patent history, request access »

Oxurion Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oxurion Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oxurion‘s full profile, request access.

Request a free trial

Oxurion Investments & Acquisitions (4)

Oxurion’s most recent deal was a Merger/Acquisition with Axiodis CRO for . The deal was made on 04-Aug-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Axiodis CRO 04-Aug-2025 Merger/Acquisition Consulting Services (B2B)
Oncurious 12-Dec-2017 Early Stage VC Drug Discovery
Oncurious 14-Apr-2015 Joint Venture Drug Discovery
ThromboGenics (TB-403 rights) 05-Jun-2012 Corporate Asset Purchase Buildings and Property
To view Oxurion’s complete investments and acquisitions history, request access »

Oxurion ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Oxurion’s complete esg history, request access »

Oxurion Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Axiodis CRO Occitanie, France 2006

Oxurion FAQs

  • When was Oxurion founded?

    Oxurion was founded in 1991.

  • Where is Oxurion headquartered?

    Oxurion is headquartered in Leuven, Belgium.

  • What is the size of Oxurion?

    Oxurion has 26 total employees.

  • What industry is Oxurion in?

    Oxurion’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Oxurion a private or public company?

    Oxurion is a Public company.

  • What is Oxurion’s stock symbol?

    The ticker symbol for Oxurion is OXUR.

  • What is the current market cap of Oxurion?

    The current market capitalization of Oxurion is $255K.

  • What is Oxurion’s current revenue?

    The trailing twelve month revenue for Oxurion is $1.34M.

  • Who are Oxurion’s competitors?

    Ora (Massachusetts) and Novartis are competitors of Oxurion.

  • What is Oxurion’s annual earnings per share (EPS)?

    Oxurion’s EPS for 12 months was $0.12.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process